



What is claimed is

1) A compound of formula (I)



or a pharmaceutically acceptable salt, prodrug or metabolite thereof, wherein

A is phenyl, naphthyl, mono- or bi-cyclic heteroaryl, or a group of the formula



optionally substituted with 1-4 substituents which are independently R^1 , OR^1 , $\text{S}(\text{O})_p\text{R}^1$, $\text{C}(\text{O})\text{R}^1$, $\text{C}(\text{O})\text{OR}^1$, $\text{C}(\text{O})\text{NR}^1\text{R}^2$, halogen, hydroxy, amino, cyano, or nitro;

B is phenyl, naphthyl, or pyridyl, optionally substituted with 1-4 substituents which are independently $\text{C}_1\text{-C}_5$ linear or branched alkyl, $\text{C}_1\text{-C}_5$ linear or branched haloalkyl, $\text{C}_1\text{-C}_3$ alkoxy, hydroxy, amino, $\text{C}_1\text{-C}_3$ alkylamino, $\text{C}_1\text{-C}_6$ dialkylamino, halogen, cyano, or nitro;

L is

(a) $-(\text{CH}_2)_m\text{-O}-(\text{CH}_2)_l-$,

(b) $-(\text{CH}_2)_m\text{-(CH}_2)_l-$,

(c) $-(\text{CH}_2)_m\text{-C}(\text{O})\text{-(CH}_2)_l-$,

(d) $-(\text{CH}_2)_m\text{-NR}^3\text{-(CH}_2)_l-$,

(e) $-(\text{CH}_2)_m\text{-NR}^3\text{C}(\text{O})\text{-(CH}_2)_l-$,

(f) $-(\text{CH}_2)_m\text{-S}-(\text{CH}_2)_l-$,

(g) $-(\text{CH}_2)_m\text{-C}(\text{O})\text{NR}^3\text{-(CH}_2)_l-$, or


(h) a single bond;

m and l are integers independently selected from 0-4;

M is a pyridine ring, optionally substituted with 1-3 substituents which are independently
5 C₁-C₅ linear or branched alkyl, C₁-C₅ linear or branched haloalkyl, C₁-C₃ alkoxy, hydroxy, amino, C₁-C₃ alkylamino, C₁-C₆ dialkylamino, halogen, or nitro;

Q is:

- 10 (1) C(S)NR⁴R⁵;
(2) C(O)NR⁷-NR⁴R⁵;
(3) tetrazolyl;
(4) imidazolyl;
(5) imidazoline-2-yl;
15 (6) 1,3,4-oxadiazoline-2-yl;
(7) 1,3-thiazoline-2-yl;
(8) 5-thioxo-4,5-dihydro-1,3,4-thiazoline-2-yl;
(9) 5-oxo-4,5-dihydro-1,3,4-oxadiazoline-2-yl; or
(10) a group of the formula



wherein each of R¹, R², R³, R⁴ and R⁵ is independently

- (a) hydrogen,
25 (b) C₁-C₅ linear, branched, or cyclic alkyl,
(c) phenyl,
(d) C₁-C₃ phenyl-alkyl,

(e) up to per-halo substituted C₁-C₅ linear or branched alkyl, or
(f) -(CH₂)_q-X, where X is a 5 or 6 membered heterocyclic ring, containing at least one atom selected from oxygen, nitrogen and sulfur, which is saturated, partially saturated, or aromatic, or a 8-10 membered bicyclic heteroaryl having 1-4 heteroatoms selected from the group consisting of O, N and S;

R⁴ and R⁵ may additionally be taken together to form a 5 or 6 membered aliphatic ring, which may be interrupted by an atom selected from N, O or S, optionally substituted with 1-3 substituents which are independently C₁-C₅ linear or branched alkyl, up to perhalo substituted C₁-C₅ linear or branched alkyl, C₁-C₃ alkoxy, hydroxy, oxo, carboxy, amino, C₁-C₃ alkylamino, C₁-C₆ dialkylamino, halogen, cyano, or nitro;

R⁶ is independently

- (a) hydrogen,
- (b) C₁-C₅ linear, branched, or cyclic alkyl,
- (c) cyano,
- (d) nitro,
- (e) up to per-halo substituted C₁-C₅ linear or branched alkyl. or
- (f) -C(O)R⁷, where R⁷ is C₁-C₅ linear, branched, or cyclic alkyl;

R⁷ is hydrogen or linear, branched, or cyclic C₁-C₅ alkyl;

q is an integer 0, 1, 2, 3, or 4 and
p is an integer 0, 1, or 2.

2) A compound of claim 1 wherein B is phenyl or pyridinyl, optionally substituted with 1-4 halogen.

3) A compound of claim 1 wherein L is -O- and B is phenyl or pyridinyl, optionally substituted with 1-4 halogen.

4) A compound of claim 1 wherein A is phenyl, naphthyl, indazolyl, quinolinyl, pyridyl, benzo[1,3]dioxolan-5-yl, 2,3-dihydro-benzo[1,4]dioxin-6-yl or 4H-benzo[1,3]dioxin-6-yl, optionally substituted with 1-4 substituents which are independently R¹ and halogen, L is -O- and B is phenyl, optionally substituted with 1-4 halogen.

5) A compound of claim 1 wherein A and B follow one of the following combinations:

A= phenyl and B= phenyl,
A= indazolyl and B= phenyl,
A= quinolinyl and B= phenyl,
A= 4H-benzo[1,3]dioxin-6-yl and B= phenyl;

A= phenyl and B= pyridyl,
A= indazolyl and B= pyridyl,
A= quinolinyl and B= pyridyl, or
A= 4H-benzo[1,3]dioxin-6-yl and B= pyridyl.

6) A compound which is

- N-[4-chloro-3-(trifluoromethyl)phenyl]-N'-(4-{{2-(hydrazinocarbonyl)pyridin-4-yl}oxy}phenyl)urea
- N-(4-{{2-(hydrazinocarbonyl)pyridin-4-yl}oxy}phenyl)-N'-(2,2,4,4-tetrafluoro-4H-1,3-benzodioxin-6-yl)urea

- N-[4-chloro-3-(trifluoromethyl)phenyl]-N'-[3-({2-[(2,2-dimethylhydrazino)carbonyl]pyridin-4-yl}oxy)phenyl]urea
- 4-{3-[[[4-chloro-3-(trifluoromethyl)phenyl]amino}carbonyl]amino]phenoxy}-N-piperidin-1-ylpyridine-2-carboxamide
- 5 • N-piperidin-1-yl-4-[3-({[(2,2,4,4-tetrafluoro-4H-1,3-benzodioxin-6-yl)amino]carbonyl}amino)phenoxy]pyridine-2-carboxamide
- 4-{3-[[[4-chloro-3-(trifluoromethyl)phenyl]amino}carbonyl]amino]phenoxy}-N-morpholin-4-ylpyridine-2-carboxamide
- N-morpholin-4-yl-4-[3-({[(2,2,4,4-tetrafluoro-4H-1,3-benzodioxin-6-yl)amino]carbonyl}amino)phenoxy]pyridine-2-carboxamide
- 10 • 4-[3-({[(1-methyl-1H-indazol-5-yl)amino]carbonyl}amino)phenoxy]-N-morpholin-4-ylpyridine-2-carboxamide
- N-[4-chloro-3-(trifluoromethyl)phenyl]-N'-(4-{[2-(1H-tetrazol-5-yl)pyridin-4-yl]oxy}phenyl)urea
- 15 • N-[4-chloro-3-(trifluoromethyl)phenyl]-N'-(4-{[2-(4,5-dihydro-1H-imidazol-2-yl)pyridin-4-yl]oxy}phenyl)urea
- N-[4-chloro-3-(trifluoromethyl)phenyl]-N'-(4-{[2-(1,3,4-oxadiazol-2-yl)pyridin-4-yl]oxy}phenyl)urea
- N-[4-chloro-3-(trifluoromethyl)phenyl]-N'-(4-{[2-(4-methyl-1,3-thiazol-2-yl)pyridin-4-yl]oxy}phenyl)urea
- 20 • N-quinolin-6-yl-N'-(4-{[2-(5-thioxo-4,5-dihydro-1,3,4-thiadiazol-2-yl)pyridin-4-yl]oxy}phenyl)urea
- N-[4-chloro-3-(trifluoromethyl)phenyl]-N'-(4-{[2-(5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)pyridin-4-yl]oxy}phenyl)urea
- 25 • N-(4-{[2-(5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)pyridin-4-yl]oxy}phenyl)-N'-(2,2,4,4-tetrafluoro-4H-1,3-benzodioxin-6-yl)urea
- 4-{4-[[[4-chloro-3-(trifluoromethyl)phenyl]amino}carbonyl]amino]phenoxy}-N-methylpyridine-2-carboximidamide
- 4-{4-[[[4-chloro-3-(trifluoromethyl)phenyl]amino}carbonyl]amino]phenoxy}pyridine-2-carboximidamide
- 30

- N-methyl-4-[4-(((2,2,4,4-tetrafluoro-4H-1,3-benzodioxin-6-yl)amino)carbonyl)amino)phenoxy]pyridine-2-carboximidamide
- N-methyl-4-(4-(((quinolin-6-ylamino)carbonyl)amino)phenoxy)pyridine-2-carboximidamide
- 5 • 4-{4-(((4-chloro-3-(trifluoromethyl)phenyl)amino)carbonyl)amino}phenoxy]pyridine-2-carbothioamide
- 4-(4-(((quinolin-6-ylamino)carbonyl)amino)phenoxy)pyridine-2-carbothioamide or
- 4-[4-(((1-methyl-1H-indazol-5-yl)amino)carbonyl)amino]phenoxy]pyridine-2-carbothioamide

10

7) A pharmaceutical composition which comprises an effective amount of at least one compound of claim 1 and a physiologically acceptable carrier.

8) A method for treating or preventing a hyper-proliferative disorder in a human or other mammal comprising administering to a human or other mammal in need thereof a compound of claim 1.

9) A method for treating or preventing a hyper-proliferative disorder in a human or other mammal comprising administering to a human or other mammal in need thereof a compound of claim 1 and an additional anti-proliferative agent.

10) A method for treating or preventing cancer in a human or other mammal comprising administering to a human or other mammal in need thereof a compound of claim 1 and a cytotoxic agent or cytostatic chemotherapeutic agent.

25

11) A method for treating or preventing a disease in a human or other mammal regulated by tyrosine kinase, associated with an aberration in the tyrosine kinase signal transduction pathway, comprising administering to a human or other mammal in need thereof a compound of claim 1.

30

12) A method for treating or preventing a disease in a human or other mammal mediated by the VEGF-induced signal transduction pathway, comprising administering to a human or other mammal in need thereof a compound of claim 1.

5 13) A method for treating or preventing a disease in a human or other mammal characterized by abnormal angiogenesis or hyperpermeability processes, comprising administering to a human or other mammal in need thereof a compound of claim 1.

10 14) A method for treating or preventing a disease in a human or other mammal characterized by abnormal angiogenesis or hyperpermeability processes, comprising administering to a human or other mammal in need thereof a compound of claim 1 simultaneously with another angiogenesis inhibiting agent in the same formulation or in separate formulations.

15 15) A method for treating or preventing one or more of the following conditions in humans and/or other mammals: tumor growth, retinopathy, ischemic retinal-vein occlusion, retinopathy of prematurity, age related macular degeneration; rheumatoid arthritis, psoriasis, a bolos disorder associated with subepidermal blister formation, including bullous pemphigoid, erythema multiforme, or dermatitis herpetiformis, 20 comprising administering to a human or other mammal in need thereof a compound of claim 1.

25 16) A method for treating or preventing one or more of the following conditions in humans and/or other mammals: tumor growth, retinopathy, diabetic retinopathy, ischemic retinal-vein occlusion, retinopathy of prematurity, age related macular degeneration; rheumatoid arthritis, psoriasis, bullous disorder associated with subepidermal blister formation, bullous pemphigoid, erythema multiforme, and dermatitis herpetiformis, in combination with an infectious disease selected from the 30 group consisting of: tuberculosis, Helicobacter pylori infection during peptic ulcer disease, Chaga's disease resulting from Trypanosoma cruzi infection, effects of Shiga-

like toxin resulting from *E. coli* infection, effects of enterotoxin A resulting from *Staphylococcus* infection, meningococcal infection, and infections from *Borrelia burgdorferi*, *Treponema pallidum*, cytomegalovirus, influenza virus, Theiler's encephalomyelitis virus, and the human immunodeficiency virus (HIV),

5 said method comprising administering to a human or other mammal in need thereof a compound of claim 1.

17) A method for treating or preventing diseases mediated by the VEGF-induced signal transduction pathway comprising administering a compound selected from the group consisting of:

- 4-{4-[3-(4-Chloro-3-trifluoromethyl-phenyl)-ureido]-phenoxy}-pyridine-2-carbothioic acid amide;
- 4-{3-[3-(2,2,4,4-Tetrafluoro-4H-benzo[1,3]dioxin-6-yl)-ureido]-phenoxy}-pyridine-2-carboxylic acid (1-piperidyl)-amide;
- 15 • 4-{3-[3-(2,2,4,4-Tetrafluoro-4H-benzo[1,3]dioxin-6-yl)-ureido]-phenoxy}-pyridine-2-carboxylic acid (4-morpholino)-amide;
- 4-{3-[3-(1-Methyl-1H-indazol-5-yl)-ureido]-phenoxy}-pyridine-2-carboxylic acid (4-morpholino)-amide;
- 4-{4-[3-(4-Chloro-3-trifluoromethyl-phenyl)-ureido]-phenoxy}-pyridine-2-
- 20 carboxamidine;
- 1-(4-Chloro-3-trifluoromethyl-phenyl)-3-{4-[2-(1H-tetrazol-5-yl)-pyridinyl-4-oxy]-phenyl}-urea;
- 1-(4-Chloro-3-trifluoromethyl-phenyl)-3-{4-[2-(4,5-dihydro-1H-imidazol-2-yl)-pyridinyl-4-oxy]-phenyl}-urea;
- 25 • 4-{4-[3-(4-Chloro-3-trifluoromethyl-phenyl)-ureido]-phenoxy}-N-methyl-pyridine-2-carboxamidine;


or a salt form, prodrug or metabolite thereof.

18) A method for treating or preventing cancer comprising administering a compound selected from the group consisting of:

- N-[4-chloro-3-(trifluoromethyl)phenyl]-N'-(4-{[2-(hydrazinocarbonyl)pyridin-4-yl]oxy}phenyl)urea
- N-(4-{[2-(hydrazinocarbonyl)pyridin-4-yl]oxy}phenyl)-N'-(2,2,4,4-tetrafluoro-4H-1,3-benzodioxin-6-yl)urea
- 5 • N-[4-chloro-3-(trifluoromethyl)phenyl]-N'-[3-({2-[(2,2-dimethylhydrazino)carbonyl]pyridin-4-yl}oxy)phenyl]urea
- 4-{3-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino}phenoxy}-N-piperidin-1-ylpyridine-2-carboxamide
- N-piperidin-1-yl-4-[3-({[(2,2,4,4-tetrafluoro-4H-1,3-benzodioxin-6-yl)amino]carbonyl}amino)phenoxy]pyridine-2-carboxamide
- 10 • 4-{3-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino}phenoxy}-N-morpholin-4-ylpyridine-2-carboxamide
- N-morpholin-4-yl-4-[3-({[(2,2,4,4-tetrafluoro-4H-1,3-benzodioxin-6-yl)amino]carbonyl}amino)phenoxy]pyridine-2-carboxamide
- 15 • 4-[3-({[(1-methyl-1H-indazol-5-yl)amino]carbonyl}amino)phenoxy]-N-morpholin-4-ylpyridine-2-carboxamide
- N-[4-chloro-3-(trifluoromethyl)phenyl]-N'-(4-{[2-(1H-tetrazol-5-yl)pyridin-4-yl]oxy}phenyl)urea
- N-[4-chloro-3-(trifluoromethyl)phenyl]-N'-(4-{[2-(4,5-dihydro-1H-imidazol-2-yl)pyridin-4-yl]oxy}phenyl)urea
- 20 • N-[4-chloro-3-(trifluoromethyl)phenyl]-N'-(4-{[2-(1,3,4-oxadiazol-2-yl)pyridin-4-yl]oxy}phenyl)urea
- N-[4-chloro-3-(trifluoromethyl)phenyl]-N'-(4-{[2-(4-methyl-1,3-thiazol-2-yl)pyridin-4-yl]oxy}phenyl)urea
- 25 • N-quinolin-6-yl-N'-(4-{[2-(5-thioxo-4,5-dihydro-1,3,4-thiadiazol-2-yl)pyridin-4-yl]oxy}phenyl)urea
- N-[4-chloro-3-(trifluoromethyl)phenyl]-N'-(4-{[2-(5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)pyridin-4-yl]oxy}phenyl)urea
- N-(4-{[2-(5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)pyridin-4-yl]oxy}phenyl)-N'-(2,2,4,4-tetrafluoro-4H-1,3-benzodioxin-6-yl)urea
- 30

- 4-{4-[[{4-chloro-3-(trifluoromethyl)phenyl}amino}carbonyl]amino]phenoxy}-N-methylpyridine-2-carboximidamide
- 4-{4-[[{4-chloro-3-(trifluoromethyl)phenyl}amino}carbonyl]amino]phenoxy}pyridine-2-carboximidamide
- 5 • N-methyl-4-[4-({(2,2,4,4-tetrafluoro-4H-1,3-benzodioxin-6-yl)amino}carbonyl)amino]phenoxy]pyridine-2-carboximidamide
- N-methyl-4-(4-{{(quinolin-6-ylamino)carbonyl}amino}phenoxy)pyridine-2-carboximidamide
- 4-{4-[[{4-chloro-3-(trifluoromethyl)phenyl}amino}carbonyl]amino]phenoxy}pyridine-2-carbothioamide
- 10 • 4-(4-{{(quinolin-6-ylamino)carbonyl}amino}phenoxy)pyridine-2-carbothioamide
- 4-[4-({(1-methyl-1H-indazol-5-yl)amino}carbonyl)amino]phenoxy]pyridine-2-carbothioamide, or a salt form, prodrug or metabolite thereof.

15 19) A compound of formula (I)






I


or a pharmaceutically acceptable salt, prodrug or metabolite thereof, wherein

20

A is



or



wherein A is optionally substituted with 1-4 substituents which are independently R^1 , OR^1 , $S(O)_pR^1$, $C(O)R^1$, $C(O)OR^1$, $C(O)NR^1R^2$, halogen, hydroxy, amino, cyano, or nitro;

5 B is phenyl, naphthyl, or pyridyl, optionally substituted with 1-4 substituents which are independently C_1 - C_5 linear or branched alkyl, C_1 - C_5 linear or branched haloalkyl, C_1 - C_3 alkoxy, hydroxy, amino, C_1 - C_3 alkylamino, C_1 - C_6 dialkylamino, halogen, cyano, or nitro;

10 L is

(a) $-(CH_2)_m-O-(CH_2)_l-$,

(b) $-(CH_2)_m-(CH_2)_l-$,

(c) $-(CH_2)_m-C(O)-(CH_2)_l-$,

(d) $-(CH_2)_m-NR^3-(CH_2)_l-$,

15 (e) $-(CH_2)_m-NR^3C(O)-(CH_2)_l-$,

(f) $-(CH_2)_m-S-(CH_2)_l-$,

(g) $-(CH_2)_m-C(O)NR^3-(CH_2)_l-$, or

(h) a single bond;

20 m and l are integers independently selected from 0-4;

M is a pyridine ring, optionally substituted with 1-3 substituents which are independently C_1 - C_5 linear or branched alkyl, C_1 - C_5 linear or branched haloalkyl, C_1 - C_3 alkoxy, hydroxy, amino, C_1 - C_3 alkylamino, C_1 - C_6 dialkylamino, halogen, or nitro;

25

Q is:


(1) $C(S)NR^4R^5$;

(2) $C(O)NR^7-NR^4R^5$;

30 (3) tetrazolyl;

(4) imidazolyl;

- (5) imidazoline-2-yl;
- (6) 1,3,4-oxadiazoline-2-yl;
- (7) 1,3-thiazoline-2-yl;
- (8) 5-thioxo-4,5-dihydro-1,3,4-thiazoline-2-yl;
- 5 (9) 5-oxo-4,5-dihydro-1,3,4-oxadiazoline-2-yl; or
- (10) a group of the formula



wherein each of R^1 , R^2 , R^3 , R^4 and R^5 is independently

- (a) hydrogen,
- (b) C_1 - C_5 linear, branched, or cyclic alkyl,
- (c) phenyl,
- (d) C_1 - C_3 phenyl-alkyl,
- 15 (e) up to per-halo substituted C_1 - C_5 linear or branched alkyl, or
- (f) $-(\text{CH}_2)_q\text{-X}$, where X is a 5 or 6 membered heterocyclic ring, containing at least one atom selected from oxygen, nitrogen and sulfur, which is saturated, partially saturated, or aromatic, or a 8-10 membered bicyclic heteroaryl having 1-4 heteroatoms selected from the group consisting of O, N and S;

R^4 and R^5 may additionally be taken together to form a 5 or 6 membered aliphatic ring, which may be interrupted by an atom selected from N, O or S, optionally substituted with 1-3 substituents which are independently C_1 - C_5 linear or branched alkyl, up to perhalo substituted C_1 - C_5 linear or branched alkyl, C_1 - C_3 alkoxy, hydroxy, oxo, carboxy, amino, C_1 - C_3 alkylamino, C_1 - C_6 dialkylamino, halogen, cyano, or nitro;

R⁶ is independently

(a) hydrogen,

(b) C₁-C₅ linear, branched, or cyclic alkyl,

5 (c) cyano,

(d) nitro,

(e) up to per-halo substituted C₁-C₅ linear or branched alkyl. or

(f) -C(O)R⁷, where R⁷ is C₁-C₅ linear, branched, or cyclic alkyl;

10 R⁷ is hydrogen or linear, branched, or cyclic C₁-C₅ alkyl;

q is an integer 0, 1, 2, 3, or 4 and

p is an integer 0, 1, or 2.

15 20) A compound of claim 19 wherein B is phenyl or pyridinyl, optionally substituted with 1-4 halogen.

21) A compound of claim 19 wherein L is -O- and B is phenyl or pyridinyl, optionally substituted with 1-4 halogen.

20


22) A compound as in claim 19 wherein B is phenyl or pyridyl, L is -O-, M a pyridine ring substituted only by Q, and Q is

C(S)NR⁴R⁵;

25 C(O)NR⁷-NR⁴R⁵;

or

a group of the formula




with each of R^4 and R^5 , independently:

- 5 (a) hydrogen,
- (b) C_1 - C_5 linear, branched, or cyclic alkyl,
- (c) phenyl,
- (d) C_1 - C_3 phenyl-alkyl,
- (e) up to per-halo substituted C_1 - C_5 linear or branched alkyl, or
- 10 (f) $-(CH_2)_q-X$, where the substituent X is pyridinyl and the variable q is preferably an integer 0 or 1, and

R^6 is:


- 15 (a) hydrogen,
- (b) C_1 - C_5 linear, branched, or cyclic alkyl, or
- (c) cyano.

23) A compound of formula (I)




or a pharmaceutically acceptable salt, prodrug or metabolite thereof, wherein

A is



or



wherein A is optionally substituted with 1-4 substituents which are independently R¹, OR¹, or halogen;

- 5 B is phenyl or pyridinyl, optionally substituted with 1-4 substituents which are independently C₁-C₅ linear or branched alkyl, C₁-C₅ linear or branched haloalkyl, C₁-C₃ alkoxy, hydroxy, amino, C₁-C₃ alkylamino, C₁-C₆ dialkylamino, halogen, cyano, or nitro,


L is -O-,

10

M is a pyridine ring,

Q is:

- 15 (1) C(S)NR⁴R⁵;
(2) C(O)NR⁷-NR⁴R⁵;
(3) tetrazolyl;
(4) imidazolyl;
(5) imidazoline-2-yl;
20 (6) 1,3,4-oxadiazoline-2-yl;
(7) 1,3-thiazoline-2-yl;
(8) 5-thioxo-4,5-dihydro-1,3,4-thiazoline-2-yl;
(9) 5-oxo-4,5-dihydro-1,3,4-oxadiazoline-2-yl; or
(10) a group of the formula



wherein each of R¹, R⁴ and R⁵ is independently

- (a) hydrogen,
- (b) C₁-C₅ linear, branched, or cyclic alkyl,
- (c) phenyl,
- (d) C₁-C₃ phenyl-alkyl,
- 5 (e) up to per-halo substituted C₁-C₅ linear or branched alkyl, or
- (f) -(CH₂)_q-X, where X is a 5 or 6 membered heterocyclic ring, containing at least one atom selected from oxygen, nitrogen and sulfur, which is saturated, partially saturated, or aromatic, or a 8-10 membered bicyclic heteroaryl having 1-4 heteroatoms selected from the group consisting of O, N and S;

10

R⁴ and R⁵ may additionally be taken together to form a 5 or 6 membered aliphatic ring, which may be interrupted by an atom selected from N, O or S, optionally substituted with 1-3 substituents which are independently C₁-C₅ linear or branched alkyl, up to

15 perhalo substituted C₁-C₅ linear or branched alkyl, C₁-C₃ alkoxy, hydroxy, oxo, carboxy, amino, C₁-C₃ alkylamino, C₁-C₆ dialkylamino, halogen, cyano, or nitro;

R⁶ is independently

- (a) hydrogen,
- 20 (b) C₁-C₅ linear, branched, or cyclic alkyl,
- (c) cyano,
- (d) nitro,
- (e) up to per-halo substituted C₁-C₅ linear or branched alkyl. or
- (f) -C(O)R⁷, where R⁷ is C₁-C₅ linear, branched, or cyclic alkyl;

25

R⁷ is hydrogen or linear, branched, or cyclic C₁-C₅ alkyl;

q is an integer 0, 1, 2, 3, or 4 and

p is an integer 0, 1, or 2.


30

24) A compound of claim 23 wherein B is phenyl or pyridinyl, substituted with 1-4 halogen.

25) A compound as in claim 23 wherein
M a pyridine ring substituted only by Q, and Q is
 $C(S)NR^4R^5$;
 $C(O)NR^7-NR^4R^5$;

or

a group of the formula



with each of R^4 and R^5 , independently:

(a) hydrogen,

(b) C_1 - C_5 linear, branched, or cyclic alkyl,

(c) phenyl,

(d) C_1 - C_3 phenyl-alkyl,

(e) up to per-halo substituted C_1 - C_5 linear or branched alkyl, or

(f) $-(CH_2)_q-X$, where the substituent X is pyridinyl and the variable q is preferably an integer 0 or 1, and

R^6 is:

(a) hydrogen,

(b) C_1 - C_5 linear, branched, or cyclic alkyl, or

(c) cyano.